COCP — Cocrystal Pharma Share News
0.000.00%
Last trade - 00:00Cocrystal Pharma Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Cocrystal Pharma’s CC-42344 Shows Strong Antiviral Potency Against 2024 H5n1 Avian Influenza Strain
Cocrystal Pharma Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Cocrystal Pharma Q1 Net Income USD -2.301 Million
Cocrystal Pharma Inc expected to post a loss of 50 cents a share - Earnings Preview
Brief: Cocrystal Pharma FY Net Income USD -17.504 Million
Cocrystal Pharma Inc expected to post a loss of 53 cents a share - Earnings Preview
Brief: Cocrystal Pharma Reports Phase 1 Results With Oral, Broad-Acting Antiviral Drug CDI-988 For Prophylaxis And Treatment Of Norovirus, Coronaviruses And Other Viral Infections
Cocrystal Pharma Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Cocrystal Pharma Q3 Net Income USD -4.939 Million
Cocrystal Pharma Inc expected to post a loss of 57 cents a share - Earnings Preview
Brief: Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor Cdi-988 Into Phase 1 Multiple-Ascending Dose Cohorts
Cocrystal Pharma Inc reports results for the quarter ended in June - Earnings Summary
Brief: Cocrystal Pharma Q2 Net Income USD -5.343 Million
Brief: Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988
Brief: Cocrystal Pharma Reported New Broad-Spectrum Antiviral May Be Effective Against The H5n1 Avian Influenza Strain
Cocrystal Pharma Inc reports results for the quarter ended in March - Earnings Summary
Brief: Cocrystal Pharma Q1 Net Income USD -3.956 Million
Cocrystal Pharma Inc expected to post a loss of 54 cents a share - Earnings Preview